...
首页> 外文期刊>Neurosurgical focus >Cushing's disease: predicting long-term remission after surgical treatment
【24h】

Cushing's disease: predicting long-term remission after surgical treatment

机译:库欣病:预测手术治疗后的长期缓解

获取原文
           

摘要

Cushing's disease (CD) is a state of excess glucocorticoid production resulting from an adrenocorticotropic hormone (ACTH)–secreting pituitary adenoma. The gold-standard treatment for CD is transsphenoidal adenomectomy. In the hands of an experienced neurosurgeon, gross-total resection is possible in the majority of ACTH-secreting pituitary adenomas, with early postoperative remission rates ranging from 67% to 95%. In contrast to the strong data in support of resection, the clinical course of postsurgical persistent or recurrent disease remains unclear. There is significant variability in recurrence rates, with reports as high as 36% with a mean time to recurrence of 15–50 months. It is therefore important to develop biochemical criteria that define postsurgical remission and that may provide prognosis for long-term recurrence. Despite the use of a number of biochemical assessments, there is debate regarding the accuracy of these tests in predicting recurrence. Here, the authors review the various biochemical criteria and assess their utility in predicting CD recurrence after resection.
机译:库欣病(CD)是分泌促肾上腺皮质激素(ACTH)分泌的垂体腺瘤导致糖皮质激素分泌过多的一种状态。 CD的金标准治疗是经蝶窦腺切除术。在有经验的神经外科医师的手中,大多数ACTH分泌型垂体腺瘤可进行全切术,术后早期缓解率在67%至95%之间。与支持切除术的强大数据相反,术后持续性或复发性疾病的临床过程仍不清楚。复发率存在显着差异,报告高达36%,平均复发时间为15-50个月。因此,重要的是要制定可定义术后缓解并可能为长期复发提供预后的生化指标。尽管使用了许多生化评估方法,但有关这些测试在预测复发方面的准确性仍存在争议。在这里,作者回顾了各种生化标准并评估了它们在预测切除后CD复发中的效用。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号